June 8, 2010 – A recent study found a potential new molecular imaging agent combined with post-scan image processing technology could result in crisper pictures of the heart. The results were revealed yesterday at the Society of Nuclear Medicine (SNM) annual meeting in Salt Lake City.

June 7, 2010 – St. Jude Medical and two hospitals agreed to pay $3.7 million to resolve allegations it paid illegal kickbacks to two hospitals to secure heart-device business, the Justice Department (DOJ) said. The government alleges the kickbacks caused false claims to be submitted to federal health care programs in violation of the False Claims Act.

June 7, 2010 – Low-dose, flat-panel computed tomography (CT) iterative reconstruction was added to the BrightView XCT single photon emission computed tomography (SPECT)/CT system. The Full Iterative Technology (FIT) feature improves localization through better uniformity and less noise, leading to improvements in soft tissue image quality.

June 7, 2010 – A program proactively monitors molecular imaging system performance online and in real-time to help predict scanner breakdowns. The system can also detect the majority of potential computed tomography (CT) tube failures.

June 4, 2010 – One-year mortality rates were very low for 1,038 high-risk patients, many of whom were too sick to undergo traditional open-heart surgery, who received the Sapien transcatheter heart valve. Results of the SOURCE Registry were presented last week at EuroPCR in Paris.

June 4, 2010 – Speech understanding technology that accepts data and translates additional physician dictation in real time into a structured document was introduced yesterday at the Annual Meeting of the Society of Imaging Informatics in Medicine (SIIM) in Minneapolis.

June 4, 2010 – The first national contract signed for a magnetic resonance imaging angiography (MRA) contrast agent was been signed, making it available to more than 27,000 medical facilities.

June 4, 2010 – A monthly, online service was launched today that allows clinicians to review and interpret general and cardiac nuclear medicine studies from anywhere in the world for a low monthly rate. The Medx Web Viewer permits interpretation of any original equipment manufacturer (OEM) dataset with nuclear medicine-specific color tables and cine movie displays.

June 3, 2010 – Six-month data from the first 45 patients enrolled in the second stage of a trial for a bioresorbable stent demonstrated strong results. Abbott's bioresorbable vascular scaffold (BVS) showed a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots.

June 3, 2010 – A joint research agreement will explore the targeted delivery of experimental therapeutics based on ribonucleic acid (RNA) interference (RNAi). Philips Healthcare and RXi Pharmaceuticals Corp. say imaging compounds based on RNAi represent a promising new class of drugs for the targeted treatment of a number of diseases including cancer and cardiovascular disease.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now